Author

Ela Talpes

Institution: Amgen (United States)

Observed institution: Amgen (United States)

OpenAlex ID: A5116248369

Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials

2025 · Qian Shi, Bruno Paiva, et al. · Journal of Clinical Oncology · 44

Works count: 1

Citation count: 44

H-index: 1

I10-index: 1